@article {BrodieP06.097作者={马丁•布罗迪和杰奎琳法国和苏珊·麦克唐纳和安德鲁·斯科特和Wen-Jene李和Virinder诺瑞亚和莎拉DeRossett}, title ={辅助使用Ezogabine / Retigabine与传统的钠离子通道阻滞剂或Non-Sodium通道阻滞剂抗癫痫药物疗效评价(P06.097)},体积={78}={1}补充数量,页面= {P06.097——P06.097} ={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估辅助使用Ezogabine / Retigabine的功效(EZG /轮胎式龙门吊)与传统的钠离子通道阻滞剂vs Non-Sodium通道阻滞剂抗癫痫药物(aed)。首页背景EZG /轮胎式龙门吊(600、900、或1200毫克/天)是有效和普遍容忍作为辅助治疗成人患者部分性癫痫发作。通过背景AED之前报道功效;然而,数据感到困惑的主题采取多个aed不同机制的行动。设计/方法:数据从三个关键EZG /轮胎式龙门吊的对照试验(研究205、301 (NCT00232596),和302年[NCT00235755])是集成和受试者接受传统的钠离子通道阻滞剂aed只有或non-sodium通道阻滞剂aed只进行了评估。疗效评估的应答率(> = 50 \ %减少基线发作频率)在维护阶段,在28天总部分发作频率变化百分比从基线到双盲(维护+滴定法)。由于小数量的科目在每组,结合数据对所有剂量(600、900和1200毫克/天)。结果:1240例的综合数据集,344(28 \ %)只采取一个或更多的钠离子通道阻滞剂aed 196(16 \ %)在一个或多个non-sodium通道阻滞剂aed。基线特征和人口结构是相似的两个子组。子组之间疗效相似,以中位数百分比减少癫痫发作的双盲治疗期(钠离子通道阻滞剂aed: EZG /轮胎式龙门吊,36 \ %,安慰剂,14 \ %;non-sodium通道阻滞剂aed: EZG /轮胎式龙门吊,45 \ %,安慰剂,21 \ %)和应答率在维护阶段(钠离子通道阻滞剂aed: EZG /轮胎式龙门吊,46 \ %,安慰剂,29 \ %; non-sodium channel blocker AEDs: EZG/RTG, 48\%, placebo, 27\%). Adjunctive use of EZG/RTG was generally tolerated in both subgroups.Conclusions: The efficacy of EZG/RTG as adjunctive treatment is similar with either traditional sodium channel blocker AEDs or non-sodium channel blocker AEDs in adults with drug-resistant partial-onset seizures.Supported by: Valeant Pharmaceuticals International and GlaxoSmithKline.Disclosure: Dr. Brodie has received personal compensation for activities with Pfizer Inc, UCB Pharma, Eisai Inc., GlaxoSmithKline, Inc., Sanofi-Aventis Pharmaceuticals, Inc., and Lundbeck Research USA, Inc. Dr. Brodie has received research support from Eisai Inc. Dr. French has nothing to disclose. Ms. McDonald has received personal compensation for activities with GlaxoSmithKline as an employee. Ms. McDonald holds stock and/or stock options inGlaxoSmithKline. Dr. Scott has received personal compensation for activities with Valeant Pharmaceuticals and GlaxoSmithKline. Dr. Scott holds stock and/or stock options in GlaxoSmithKline. Dr. Lee has received personal compensation for activities with GlaxoSmithKline as an employee. Dr. Lee holds stock and/or stock options in GlaxoSmithKline. Dr. Nohria has received personal compensation for activities with Valeant Pharmaceuticals, GlaxoSmithKline, Inc., Marinus Pharma, and UCB Pharma. Dr. DeRossett has received personal compensation for activities with GlaxoSmithKline as an employee.Dr. DeRossett holds stock and/or stock options in GlaxoSmithKline.Thursday, April 26 2012, 07:30 am-12:00 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/P06.097}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }